Chrysosplenetin

Chrysosplenetin at a Glance

Chrysosplenetin is a polymethoxylated flavonol of sweet wormwood (Artemisia annua), and the best-evidenced member of that plant’s “synergy flavonoid” story.

On its own it is a weak antimalarial — roughly a thousandfold weaker than artemisinin. Its real activity is pharmacokinetic: it potentiates artemisinin rather than killing parasites itself, and it has been shown to reverse artemisinin resistance in resistant strains.

That makes it a rare, well-documented example of a plant compound whose function is to make another compound in the same plant work better — the mechanistic core of the argument that whole-plant Artemisia preparations behave differently from purified artemisinin.

What It's Used For

Chrysosplenetin is the molecule that carries the most weight in Artemisia annua’s most persistent claim — that the whole herb beats its isolated drug because its flavonoids potentiate artemisinin. The literature is real, specific and mechanistically detailed, and it is also entirely preclinical: in vitro antiplasmodial and antiviral work, rat pharmacokinetics, and a series of mouse studies from one Chinese group on reversing artemisinin resistance. Two facts frame everything below. First, chrysosplenetin is a poor antimalarial in its own right — around a thousandfold weaker than artemisinin ^{1Reference 1Liu et al. · 1992In vitroAntimalarial activity of Artemisia annua flavonoids from whole plants and cell cultures — in vitroView study →} — so its interest is as a modifier of another drug, not as a drug. Second, the potentiation that has been demonstrated is isolated chrysosplenetin dosed at a fixed ratio to isolated artemisinin, which is not what a tea or a capsule of dried leaf delivers; when the whole-plant version of the hypothesis was tested directly with flavonoid-deficient mutant lines, it failed ^{8Reference 8Czechowski et al. · 2019In vitroFlavonoid versus artemisinin anti-malarial activity in Artemisia annua whole-leaf extracts — in vitroView study →}.

The gap between those two statements is the entire subject.

Mechanisms

Pharmacokinetics

Chrysosplenetin’s own pharmacokinetics have not been characterised. No oral bioavailability figure, absorption study, half-life or tissue-distribution data for the isolated molecule was located — which is a striking hole given that its entire claim to relevance is a pharmacokinetic interaction with another drug. What is documented is the other side of that interaction: what chrysosplenetin does to artemisinin’s disposition in rats ^{3Reference 3Wei et al. · 2015In vitroImpact of chrysosplenetin on the pharmacokinetics and anti-malarial efficacy of artemisinin against Plasmodium berghei, and in vitro CYP450 enzymatic activities in rat liver microsome — animal model (rat and mouse)View study →}.

The extraction data are the decision-relevant substitute. Polymethoxylated flavonols are lipophilic and poorly water-soluble, and when this was measured for the sibling molecules casticin and artemetin in an A. annua tea infusion prepared by a protocol optimised for artemisinin, casticin recovery was 1.8% and artemetin was undetectable; stored 24 hours at room temperature, casticin fell a further 40% ^{9Reference 9Weathers et al. · 2012In vitroThe flavonoids casticin and artemetin are poorly extracted and are unstable in an Artemisia annua tea infusion — in vitroView study →}. Chrysosplenetin was not measured in that study, so this is an inference from close structural relatives — but it is the strongest available answer to the practical question, and it points the same way as the mutant-line result ^{8Reference 8Czechowski et al. · 2019In vitroFlavonoid versus artemisinin anti-malarial activity in Artemisia annua whole-leaf extracts — in vitroView study →}: whatever chrysosplenetin does at 10 mg/kg as an isolate, a cup of tea is not delivering it.

Clinical trials

No registered clinical trials of isolated chrysosplenetin were identified, and no human study of any kind. The evidence base is entirely preclinical — rat and mouse in vivo plus cell-culture work.

Last checked: August 2026.

Isolate vs. Plant Studies

Every finding here used the isolated molecule — purified chrysosplenetin dosed alongside purified artemisinin at controlled ratios, or applied to cells at defined micromolar concentrations. That is a strength for interpreting mechanism and a serious limitation for interpreting the herb, because the claim this molecule is invoked to support is a whole-plant claim.

The whole-plant version has been tested and did not hold. Rodent work reported that dried whole-plant A. annua raised artemisinin bioavailability and might add antiparasitic synergy ^{10Reference 10Elfawal et al. · 2012AnimalDried whole plant Artemisia annua as an antimalarial therapy — animal model (mouse)View study →}, but a York group using flavonoid-deficient mutant lines found that the antiplasmodial activity of whole-leaf extract tracked artemisinin content, with flavonoids contributing negligibly in vitro ^{8Reference 8Czechowski et al. · 2019In vitroFlavonoid versus artemisinin anti-malarial activity in Artemisia annua whole-leaf extracts — in vitroView study →}. That is the direct experiment, and it is negative for the flavonoids specifically. A 2025 study again reported that an A. annua extract outperformed equivalent isolated artemisinin with better oral bioavailability and reduced P-gp-mediated efflux ^{11Reference 11Xu et al. · 2025AnimalThe plant matrix of Artemisia annua L. for the treatment of malaria: pharmacodynamic and pharmacokinetic studies — animal model (rat and mouse)View study →} — so the plant-matrix question is not settled — but that work attributes the effect to the extract’s sesquiterpene complexity and does not identify chrysosplenetin as the agent.

The honest position: chrysosplenetin’s isolated pharmacology is genuine and its mechanism is unusually well mapped for a plant flavonol, but it does not license the inference that A. annua tea is a better antimalarial than artemisinin. Read it as molecular pharmacology, not as a reason to prefer the herb — and note that the herb page’s central caution, the WHO position against herbal A. annua for malaria on resistance grounds, is unaffected by anything here.

Prevalence in Nature

Chrysosplenetin is a polymethoxylated flavonol — structurally, quercetagetin with methyl groups on the 3, 6, 7 and 3′ positions, leaving free hydroxyls at 5 and 4′ (C₁₉H₁₈O₈, 374.3 g/mol). Methylation is the defining feature of this subclass: it raises lipophilicity and metabolic stability relative to a free-hydroxyl flavonol like quercetin, which is why polymethoxyflavones are repeatedly nominated as bioavailability modifiers rather than as antioxidants.

Its name comes from the saxifrage genus Chrysosplenium (the golden-saxifrages), but its pharmacological literature was built almost entirely on two other plants: sweet wormwood (Artemisia annua), where it sits alongside casticin, artemetin, chrysosplenol D, cirsilineol and eupatorin in the leaf flavonoid fraction, and Laggera pterodonta, the source used for the antiviral work ^{6Reference 6Zhu et al. · 2011In vitroInhibition of enterovirus 71 replication by chrysosplenetin and penduletin — in vitroView study →}. It is also reported from German chamomile (Matricaria chamomilla) ^{7Reference 7Hong et al. · 2019AnimalChrysosplenetin promotes osteoblastogenesis of bone marrow stromal cells via the Wnt/β-catenin pathway and enhances osteogenesis in estrogen deficiency-induced bone loss — animal model (mouse)View study →} and Dracocephalum heterophyllum. Biosynthetically it is an ordinary flavonol — the phenylpropanoid → chalcone → flavonol route to quercetagetin — followed by a series of O-methyltransferase steps; the methylation pattern, not the skeleton, is what distinguishes it from its siblings.

Abundance is not well quantified. No published mg/g or %-dry-weight figure for chrysosplenetin in any source plant was located. For scale, its close relative casticin has been measured at about 1.07 ± 0.23 mg/g in A. annua leaf material from eastern and northern China — a useful order-of-magnitude anchor for the flavonoid fraction, and explicitly not a chrysosplenetin figure.

Discovery & Synthesis

First isolation is not well documented. The name points at Chrysosplenium, and the compound is an established constituent of that genus, but a specific first-isolation paper and date could not be verified — so none is guessed. What is datable is its entry into pharmacology: the 1987 Elford observation that A. annua’s methoxylated flavones potentiate qinghaosu ^{2Reference 2Elford et al. · 1987In vitroPotentiation of the antimalarial activity of qinghaosu by methoxylated flavones — in vitroView study →} opened the field, and the 1992 Liu study named chrysosplenetin among the four flavonoids accounting for the antiplasmodial activity of A. annua extracts ^{1Reference 1Liu et al. · 1992In vitroAntimalarial activity of Artemisia annua flavonoids from whole plants and cell cultures — in vitroView study →}. Everything since follows from those two papers.

Manufacture today has an unusual and rather elegant answer. Chrysosplenetin used in the resistance research is described as recovered from the acetone fraction of artemisinin-extraction industrial waste ^{5Reference 5Ji et al. · 2025AnimalChrysosplenetin acts as a homeostasis stabilizer with dual function in shattering Plasmodium berghei K173 resistance to artemisinin driven by both ABC transporters and the heme-ROS/GSH axis — animal model (mouse)View study →} — a by-product of the process that makes the drug it is studied alongside. That is a plausible commercial route precisely because the co-occurrence that motivates the research also guarantees the feedstock. No total synthesis of note was located; as a tetramethylated quercetagetin it is not a difficult target, but nothing suggests synthesis competes with recovery.

Patents: not yet researched (future patent-loop pass).

Dosage

No human dose exists, and none should be inferred from what follows. Chrysosplenetin has never been administered to people as an isolate. These are the doses used in research.

The consistent finding across the antimalarial work is that the 1:2 artemisinin:chrysosplenetin ratio outperformed 1:1 and 1:4 ^{3Reference 3Wei et al. · 2015In vitroImpact of chrysosplenetin on the pharmacokinetics and anti-malarial efficacy of artemisinin against Plasmodium berghei, and in vitro CYP450 enzymatic activities in rat liver microsome — animal model (rat and mouse)View study →} — the effect depends on proportion, not just presence. Note that the bone result used intraperitoneal injection, which bypasses oral absorption and is not translatable to a swallowed dose.

These are doses studied in research and are not a personal recommendation.

Scope Disclosure

• Interactions assessed? Partly — CYP inhibition is documented in rat liver microsomes ^{3Reference 3Wei et al. · 2015In vitroImpact of chrysosplenetin on the pharmacokinetics and anti-malarial efficacy of artemisinin against Plasmodium berghei, and in vitro CYP450 enzymatic activities in rat liver microsome — animal model (rat and mouse)View study →}. No human interaction study exists, and P-gp/transporter effects are described only in rodent infection models ^{4,5Reference 4Chen et al. · 2023AnimalAntimalarial activity and sensitization of chrysosplenetin against artemisinin-resistant genotype Plasmodium berghei K173 via maintaining host P-glycoprotein homeostasis mediated by NF-κB p52 or PXR/CAR signalling and regulating heme/haemozoin metabolism — animal model (mouse)View study →Reference 5Ji et al. · 2025AnimalChrysosplenetin acts as a homeostasis stabilizer with dual function in shattering Plasmodium berghei K173 resistance to artemisinin driven by both ABC transporters and the heme-ROS/GSH axis — animal model (mouse)View study →}.
• Pregnancy/lactation assessed? No. No reproductive or developmental data for isolated chrysosplenetin were located. Pregnancy guidance for the source herb lives on the sweet wormwood page, where intake is actually decided.